The NAMPT/NAD+ pathway may be a possible therapeutic option for treating CCA cell growth alone or in combination with cisplatin, according to the results of this study, which overall point to FK866 as a potentially successful targeted CCA treatment. The gene discussed is NAMPT; the disease is cholangiocarcinoma.